TSIEX11:	Incidence and Reason for Treatment Modification for Infusions; Safety Analysis Set (Study jjcs - core)					
Time Point 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
  Time Relative to Infusion 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
    Modification, n (%) 	N=53 	N=73 	N=126 	N=59 	
Overall 	 	 	 	 	
Prior to infusion 	 	 	 	 	
N 	53 	73 	126 	59 	
Infusion delayed 	12 (22.6%) 	20 (27.4%) 	32 (25.4%) 	13 (22.0%) 	
Other 	1 (1.9%) 	0 	1 (0.8%) 	0 	
 	 	 	 	 	
Study agent permanently discontinued 	13 (24.5%) 	16 (21.9%) 	29 (23.0%) 	24 (40.7%) 	
Adverse Event 	1 (1.9%) 	0 	1 (0.8%) 	0 	
 	 	 	 	 	
During infusion 	 	 	 	 	
N 	53 	73 	126 	59 	
Infusion interrupted 	19 (35.8%) 	24 (32.9%) 	43 (34.1%) 	19 (32.2%) 	
Adverse Event 	1 (1.9%) 	0 	1 (0.8%) 	0 	
 	 	 	 	 	
Week 2 	 	 	 	 	
Prior to infusion 	 	 	 	 	
N 	53 	52 	105 	56 	
Study agent permanently discontinued 	9 (17.0%) 	3 (5.8%) 	12 (11.4%) 	9 (16.1%) 	
Adverse Event 	1 (1.9%) 	0 	1 (1.0%) 	0 	
 	 	 	 	 	
During infusion 	 	 	 	 	
N 	53 	52 	105 	56 	
Infusion interrupted 	12 (22.6%) 	12 (23.1%) 	24 (22.9%) 	11 (19.6%) 	
Adverse Event 	1 (1.9%) 	0 	1 (1.0%) 	0 	
 	 	 	 	 	
Week 24 	 	 	 	 	
Prior to infusion 	 	 	 	 	
N 	20 	15 	35 	40 	
Infusion delayed 	5 (25.0%) 	2 (13.3%) 	7 (20.0%) 	5 (12.5%) 	
Other 	1 (5.0%) 	0 	1 (2.9%) 	0 	

Note: For ‘Overall’, subjects can only be counted once in each category. 	
Note: For ‘Overall’, subjects can only be counted once in each category.	
Note: For ‘Overall’, subjects can only be counted once in each category.	
Note: For ‘Overall’, subjects can only be counted once in each category.	
Note: For ‘Overall’, subjects can only be counted once in each category.	
Note: Includes subjects who had any dose modifications during treatment. 	: Includes subjects who had any dose modifications during treatment.	: Includes subjects who had any dose modifications during treatment.	: Includes subjects who had any dose modifications during treatment.	: Includes subjects who had any dose modifications during treatment.